ImmunityBio (IBRX) Reports Q4 Loss, Misses Revenue Estimates
Portfolio Pulse from
ImmunityBio (IBRX) reported a Q4 loss of $0.15 per share, which was better than the expected loss of $0.26 per share. However, the company missed revenue estimates.
March 03, 2025 | 3:15 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
ImmunityBio reported a Q4 loss of $0.15 per share, better than the expected $0.26 loss, but missed revenue estimates. This mixed result may lead to short-term volatility in the stock price.
The better-than-expected EPS loss suggests some positive operational performance, but missing revenue estimates could concern investors. This mixed outcome is likely to cause short-term volatility in the stock price as the market digests the news.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100